Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.93 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.93 |
| ▸ | RPS17 | P08708 | 1/20 | 0.93 |
| ▸ | RPSA | P08865 | 1/20 | 0.93 |
| ▸ | RPS2 | P15880 | 1/20 | 0.93 |
| ▸ | RPL35A | P18077 | 1/20 | 0.93 |
| ▸ | RPL7 | P18124 | 1/20 | 0.93 |
| ▸ | RPL17 | P18621 | 1/20 | 0.93 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.93 |
| ▸ | RPS3 | P23396 | 1/20 | 0.93 |
| ▸ | RPS12 | P25398 | 1/20 | 0.93 |
| ▸ | RPL13 | P26373 | 1/20 | 0.93 |
| ▸ | RPL10 | P27635 | 1/20 | 0.93 |
| ▸ | RPL12 | P30050 | 1/20 | 0.93 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 1/20 | 0.93 |
| ▸ | RPL22 | P35268 | 1/20 | 0.93 |
| ▸ | RPL4 | P36578 | 1/20 | 0.93 |
| ▸ | RPS19 | P39019 | 1/20 | 0.93 |
| ▸ | RPL3 | P39023 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geneticin SCHEMBL9920496 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL15250053 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL27348589 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL16271605 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL15157128 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL23872057 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL15596 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL17586045 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL15251579 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA | |
| Geneticin SCHEMBL18722083 | 1.00 | CYP3A4 (0.93) | CYP3A4RPLP1RPLP0RPS17RPSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813739-B | Spodoptera litura lethal gene tin and application thereof | 华南农业大学 | 2024-04-26 | — | — | CN | claimed |
| CN-116934408-A | Network-connected vehicle special road setting method based on tradable electronic road ticket | 东南大学 | 2023-10-24 | — | — | CN | claimed |
| CN-116738849-A | Manufacturing resource service combination and optimization method in cloud manufacturing environment | 重庆大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116362137-A | Multi-target beam forming device optimizing method under spherical harmonic domain | 桂林电子科技大学 | 2023-06-30 | — | — | CN | claimed |
| CN-109913421-B | Construction and identification method of midkine protein stable high-expression tumor cell line | 中国科学院大连化学物理研究所 | 2022-11-08 | — | — | CN | claimed |
| US-20260139269-A1 | MATRIX ATTACHMENT REGIONS AND USES IN PROMOTING GENE EXPRESSION | CELLTHEON CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102506-A1 | EXPRESSION VECTORS AND USE THEREOF TO ENHANCE THE EFFICIENCY OF DOUBLE-STRAND BREAK INDUCED MUTAGENESIS | CENTRO NACIONAL DE PESQUISA EM ENERGIA E MATERIAIS (BR) | 2026-05-21 | — | — | WO | disclosed |
| CN-121702893-A | Non-genetic wine packaging box compression-resistant detection method and system based on sensor | 成都金航包装有限公司 | 2026-03-20 | — | — | CN | disclosed |
| CN-121702893-A | Non-genetic wine packaging box compression-resistant detection method and system based on sensor | 成都金航包装有限公司 | 2026-03-20 | — | — | CN | disclosed |
| US-20260071000-A1 | CD47-CD38 BISPECIFIC ANTIBODIES | IGI Therapeutics SA (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20260062696-A1 | CLONING AND EXPRESSION SYSTEM FOR T-CELL RECEPTORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12565663-B2 | Matrix attachment regions and uses in promoting gene expression | CELLTHEON CORPORATION (US) | 2026-03-03 | — | — | US | disclosed |
| US-7439037-B2 | Use of aminoglycoside resistance gene | Al-Rubeai, Mohamed (GB) | 2008-10-21 | — | — | US | disclosed |
| CN-100402653-C | Application of aminoglycoside resistance gene | U K LONGSHA BIO MEDICAL CO LTD (GB) | 2008-07-16 | — | — | CN | disclosed |
| US-20070093433-A1 | Aminoglycoside antibiotics for use as vap-1/ssao inhibitors | FARON PHARMACEUTICALS OY (FI) | 2007-04-26 | — | — | US | disclosed |
| EP-1438411-B1 | USE OF AMINOGLYCOSIDE RESISTANCE GENE | LONZA BIOLOGICS PLC (GB) | 2006-07-26 | — | — | EP | disclosed |
| CN-1705749-A | Application of aminoglycoside resistance gene | U K LONGSHA BIO MEDICAL CO LTD (GB) | 2005-12-07 | — | — | CN | disclosed |
| US-20050112722-A1 | Use of aminoglycoside resistance gene | LONZA BIOLOGICS PLC (GB) | 2005-05-26 | — | — | US | disclosed |
| EP-1438411-A2 | USE OF AMINOGLYCOSIDE RESISTANCE GENE | Lonza Biologics plc (GB) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003027300-A2 | USE OF AMINOGLYCOSIDE RESISTANCE GENE | LONZA BIOLOGICS PLC. (GB) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565663-B2 | Matrix attachment regions and uses in promoting gene expression | RNGTT, UPF1, MYB | CYP3A4 4857/4885RPLP1 2353/4885RPLP0 3548/4885 |
| US-20260062696-A1 | CLONING AND EXPRESSION SYSTEM FOR T-CELL RECEPTORS | IGLV6-57, TMIGD3, IGSF11 | CYP3A4 2441/4885RPLP1 2490/4885RPLP0 2280/4885 |
| US-20070093433-A1 | Aminoglycoside antibiotics for use as vap-1/ssao inhibitors | PLIN1, MACO1, APMAP | CYP3A4 3400/4885RPLP1 1640/4885RPLP0 2293/4885 |
| US-20260139269-A1 | MATRIX ATTACHMENT REGIONS AND USES IN PROMOTING GENE EXPRESSION | CTCF, PHAX, UPF1 | CYP3A4 4824/4885RPLP1 2055/4885RPLP0 1506/4885 |
| US-20260071000-A1 | CD47-CD38 BISPECIFIC ANTIBODIES | CD47, CD22, CD2 | CYP3A4 4770/4885RPLP1 2151/4885RPLP0 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.